Special Issue "The Interleukin-6 Family in Disease Pathogenesis and Therapy"
A special issue of Biomedicines (ISSN 2227-9059).
Deadline for manuscript submissions: closed (30 April 2019)
Prof. Steven E. Mutsaers
University of Western Australia Faculty of Medicine and Dentistry, Centre for Cell Therapy and Regenerative Medicine, Perth, Australia
Website | E-Mail
Interests: Pulmonary fibrosis; mesothelial cell biology; malignant mesothelioma; post-operative adhesions; disease pathogenesis; cell signalling; animal models of disease
The IL-6 family is a group of closely related pleiotropic cytokines produced by a variety of cells in response to inflammatory stimuli. They are related in structure and function and include IL-6, IL-11, leukemia inhibitory factor (LIF), Oncostatin M (OSM), ciliary neurotrophic factor (CNTF), cardiotrophin 1 (CT-1), cardiotrophin like cytokine (CLC), IL-27, IL-31, and neuropoietin. The actions of these cytokines are mediated through specific cell surface receptors and the shared signal transducing subunit, gp130. Subsequent signalling is mediated through a tight reciprocal regulation of either ERK-MAPK or JAK-STAT pathways, critical for the generation of physiological responses to IL6-family cytokines. Conversely, disturbance of this finely orchestrated signalling, leads to pathological responses. The IL-6 family stimulates the inflammatory and autoimmune processes in many diseases. Hence, there is a strong interest in developing agents against these molecules or their signalling pathways to treat disease. Articles (original and reviews) are being sought for a Special Issue highlighting the importance of the IL-6 family of cytokines in both health and disease and novel approaches to modulate their function.
Prof. Steven E. Mutsaers
Prof. Cecilia M. Prêle
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 550 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- IL-6 family cytokines
- disease pathogenesis
- signalling pathways
- STAT3, MAPK
- autoimmune disease
- neurological disease